• A-769662: Redefining AMPK Activation in Cellular Energy Stre

  2026-05-09

  Explore how A-769662, a potent AMPK activator, is transforming our understanding of energy metabolism regulation and autophagy. This article reveals new mechanistic insights and practical implications for metabolic research, setting it apart from existing resources.

• Nadolol (SQ-11725): Translational Leverage in Cardiovascular

  2026-05-08

  This thought-leadership article examines Nadolol (SQ-11725) as a cornerstone compound for translational cardiovascular research, emphasizing mechanistic insights, transporter-mediated pharmacokinetics, and strategic workflow guidance. Integrating recent advances in transporter biology and evidence from both the MASLD/MASH pharmacokinetic literature and leading research articles, the piece offers actionable protocols and a forward-looking vision for deploying Nadolol in hypertension, angina pectoris, and vascular headache models. APExBIO’s research-grade Nadolol is highlighted as a trusted standard for reproducibility and future-oriented experimental design.

• Cycloheximide in Translational Control: Beyond Apoptosis Ass

  2026-05-08

  Explore the advanced scientific landscape of Cycloheximide as a protein biosynthesis inhibitor. This in-depth review goes beyond apoptosis assays, revealing novel mechanistic insights and practical guidance for translational control and antiviral research.

• DOT1L Inhibition Enhances Lenalidomide Response in Myeloma

  2026-05-07

  This study demonstrates that DOT1L inhibition reprograms innate immune signaling in multiple myeloma, resulting in enhanced anti-myeloma efficacy of immunomodulatory drugs such as lenalidomide. The findings clarify epigenetic dependencies in myeloma and provide a mechanistic rationale for combining DOT1L inhibitors with established IMiDs to potentiate therapeutic outcomes.

• JSH-23: Precision NF-κB Inhibitor Workflows for Inflammation

  2026-05-07

  JSH-23 enables targeted inhibition of NF-κB p65 nuclear translocation, supporting high-confidence analysis of inflammatory pathways in both cell-based and animal models. This guide offers stepwise protocols, troubleshooting strategies, and advanced insights, translating the latest mechanistic discoveries into practical, reproducible assay design.

• D-Luciferin Potassium Salt: Optimizing In Vivo Imaging Workf

  2026-05-06

  D-Luciferin (potassium salt) enables ultra-sensitive, real-time in vivo bioluminescence imaging for tumor cell tracking and therapeutic monitoring. This guide unpacks experimental nuances, advanced applications, and troubleshooting strategies that elevate reproducibility and sensitivity beyond standard luciferase assays.

• Heptamethine Cyanine Dye Targets PR in HR+ Breast Cancer Mod

  2026-05-06

  This study introduces a novel heptamethine cyanine dye (CA800-PR) that induces selective suppression of the progesterone receptor in hormone receptor-positive breast cancer, leading to apoptosis and immunogenic cell death. The findings highlight a new therapeutic strategy distinct from conventional hormone therapies, with implications for overcoming resistance in HR+ breast cancer.

• Nicotinamide Riboside Chloride: Precision NAD+ Enhancement i

  2026-05-05

  Nicotinamide Riboside Chloride (NIAGEN) offers researchers a robust, high-purity NAD+ precursor to boost energy metabolism and sirtuin signaling in metabolic dysfunction and neurodegenerative workflows. Its proven compatibility with iPSC-derived retinal ganglion cell assays and Alzheimer’s models, backed by APExBIO’s rigorous quality control, delivers reproducibility and translational impact for next-generation disease research.

• Membrane-Driven Structure-Activity of ω-Agatoxin IVA in Cav2

  2026-05-05

  This study elucidates the membrane-dependent structural changes in ω-Agatoxin IVA, a funnel-web spider toxin, and their impact on selective Cav2.1 channel inhibition. Using NMR spectroscopy in membrane mimetics, the work reveals unique structural motifs critical for channel blockade, refining our understanding of gating modifier toxins and supporting advanced applications in synaptic and neuroprotection research.

• Sisomicin: Antibacterial Spectrum and Clinical Utility Revie

  2026-05-04

  This review synthesizes evidence on Sisomicin, a naturally occurring aminoglycoside antibiotic, focusing on its antibacterial spectrum, comparative efficacy, and resistance mechanisms in Gram-negative and Gram-positive infection research. The clinical and experimental data inform best practices for in vitro and translational application, with practical guidance for researchers.

• WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metab

  2026-05-04

  WY-14643 (Pirinixic Acid) is a well-characterized, selective PPARα agonist used to dissect lipid metabolism and inflammation in metabolic disorder research. Its potency, dual modulation capabilities, and reproducible effects in vivo and in vitro make it a benchmark tool for translational studies.

• Tacrolimus (FK506): Precision Immunosuppression in Research

  2026-05-03

  Tacrolimus (FK506) stands apart for its nanomolar potency and selectivity in modulating T-cell activation and cytokine signaling, making it indispensable in transplantation immunology research. This article details optimized workflows, advanced applications, and actionable troubleshooting tips that maximize reproducibility and assay sensitivity with APExBIO’s trusted Tacrolimus.

• Super-Enhancer RNA Drives Nasopharyngeal Carcinoma Metastasi

  2026-05-02

  This study identifies a carcinogen-induced super-enhancer RNA (seRNA-NPCm) that promotes nasopharyngeal carcinoma (NPC) metastasis via the NPM1/c-Myc/NDRG1 axis. The findings reveal a mechanistic link between chemical exposure, chromatin architecture, and metastatic gene activation, with implications for prognosis and biomarker development.

• Bismuth Subsalicylate (A8382): Mechanisms and Research Utili

  2026-05-02

  Bismuth Subsalicylate, also known as 1,3,2λ2-benzodioxabismin-4-one, is a high-purity, water-insoluble solid widely utilized in gastrointestinal disorder research. Its primary action as a prostaglandin G/H synthase 1/2 inhibitor underpins its anti-inflammatory and gastrointestinal protective effects, with robust benchmarks supporting its role in inflammation pathway modulation and diarrhea treatment research.

• CCL7+ Macrophages Drive Resistance to Immunotherapy in CRC

  2026-05-01

  This study uncovers the mechanistic role of CCL7-expressing tumor-associated macrophages in conferring resistance to immune checkpoint inhibitors in colorectal cancer. By delineating how CCL7 modulates immune cell infiltration and function, the findings highlight new avenues for combination immunotherapy strategies targeting the tumor microenvironment.

496 records 15/34 page Previous Next First page 上5页 1112131415 下5页 Last page